Testing continuous vs pulsed treatment for chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This early-phase study compares two ways of giving treatment for chronic hepatitis B: continuous antiviral therapy versus pulsed treatment. It may help find a schedule that works well and is tolerable for people with hepatitis B.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old (either sex).
- You have hepatitis B surface antigen (HBsAg) positive for more than 6 months.
- You’ve been on the NA antiviral medicine continuously for more than 6 months, and your hepatitis numbers fit the study levels at enrollment.
- If you are able to become pregnant, you must have a negative pregnancy test within 24 hours before the first dose and be willing to use contraception if required during the study.
- You should not have hepatitis A/C/D/E or HIV infections at the start.
- Your liver function and blood counts must be good enough (no signs of advanced/decompensated liver disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
This trial tests a sequence of pegylated interferon (PEG-IFN) shots for people with chronic hepatitis B who have already had a significant drop in their virus levels after taking a newer type of RNA-targeting medicine. The goal is to see if this approach can help clear the virus even further.
This study tests whether a long-acting interferon medication can help people with chronic hepatitis B who have already received interferon treatment clear the hepatitis B virus more completely. It's designed for patients whose virus levels dropped significantly during their first treatment but haven't gone away.
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
This trial tests a new medicine (VIR-2218) combined with a standard injection (peginterferon) to see if it can better control chronic hepatitis B. It may be an option if your virus levels are low and you haven't had recent treatment.
Hear when a new Hepatitis B, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.